Bioray Biotech Co

Bioray Biotech Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Bioray Biotech Co (7561.TWO) as of Oct 16, 2026 is 1.18. In the previous year, Financial Leverage (Equity Multiplier) was 1.29 — a change of -8.33% (lower).

Financial Leverage

1.18

YoY

-8.33%

Last updated:

Financial Leverage (Equity Multiplier) of Bioray Biotech Co is 2025 1.18 . Financial Leverage (Equity Multiplier) of Bioray Biotech Co was 2024 1.29 . It decreases by -8.33% lower compared to the previous year.

The Bioray Biotech Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.26 TWD
Jan 1, 2019
1.32 TWD
Jan 1, 2020
1.29 TWD
Jan 1, 2021
1.28 TWD
Jan 1, 2022
1.33 TWD
Jan 1, 2023
1.25 TWD
Jan 1, 2024
1.29 TWD
Jan 1, 2025
1.18 TWD
The Bioray Biotech Co Financial Leverage history
YEARFinancial LeverageYoY
1.18-8.33%
1.29+3.32%
1.25-5.68%
1.33+3.51%
1.28-0.56%
1.29-2.60%
1.32+4.59%
1.26-6.29%
1.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bioray Biotech Co Stock analysis

What does Bioray Biotech Co do? Bioray Biotech Co Ltd is a company based in Tainan, Taiwan, operating within the Health Care sector, specifically in the Biotechnology industry. The company went public on July 6, 2020, with its ticker listed as 7561.TWO and ISIN TW0007561B13. Bioray Biotech focuses on the development of biological health products, functional medical testing, and cell storage and preparation services. The company's product portfolio includes personalized probiotics, anti-allergic and intestinal probiotics, diabetes probiotics, and female urinary tract health products. In the functional medical testing segment, the company offers services such as personalized bacteria testing, personalized fungi testing, intestinal normal bacteria analysis, quantitative detection of magnesium in red blood cells, polymorphism analysis of metabolic-related genes, and lymphocyte grouping. For cell storage and preparation, Bioray Biotech provides stem cell storage, immune cell storage, and cytokine-induced killer (CIK) immune cell preparations. The company's website is https://bio-ray.com.tw/, where further information about its services and products can be found. Bioray Biotech is engaged in the development and provision of specialized health-related services and products, primarily targeting personalized health solutions through biotechnology. Bioray Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioray Biotech Co stock

Financial Leverage (Equity Multiplier) of Bioray Biotech Co is 1.18 in 2025.

Financial Leverage (Equity Multiplier) of Bioray Biotech Co changed from 1.29 to 1.18, representing a -8.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Bioray Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Bioray Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Bioray Biotech Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Bioray Biotech Co